| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/01/2006 | US20060116421 N-(3,5-bis-trifluoromethyl-benzyl)-1-(2-tert-butoxycarbonyl-amino-thiazol-4-yl)-3-(N-methyl, N-tetrahydro-4H-pyran-4-ylamino]-cyclopentanecarbamide; antiinflammatory agent; antiallergen; autoimmune diseases; allergic rhinitis, dermatitis, conjunctivitis, asthma, rheumatoid arthritis and atherosclerosis |
| 06/01/2006 | US20060116420 Crystalline forms of 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel |
| 06/01/2006 | US20060116419 Nf-kb inhibitors |
| 06/01/2006 | US20060116418 Materials and methods for treating hypercholesterolemia |
| 06/01/2006 | US20060116417 Thrombopoietin activity modulating compounds and methods |
| 06/01/2006 | US20060116416 e.g. [5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic acid; peroxisome proliferator activated receptor agonist; anticoagulant, antidiabetic agent; obesity, hyperlipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema, psoriasis |
| 06/01/2006 | US20060116415 Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators |
| 06/01/2006 | US20060116413 Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heteroyclic amide bond isostere |
| 06/01/2006 | US20060116412 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
| 06/01/2006 | US20060116411 Medicinal composition containing triazole compound |
| 06/01/2006 | US20060116410 4-Aminomethyl benzamidine derivatives |
| 06/01/2006 | US20060116409 Phospholipase inhibitors |
| 06/01/2006 | US20060116408 Chymase inhibitor; cardiovascular disorders, circulation diseases; hypotensive agents; methyl 4-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonylamino)-3-methanesulfonylbenzoate |
| 06/01/2006 | US20060116407 Amide derivatives |
| 06/01/2006 | US20060116406 e.g. 4-(4-fluorophenyl)-7-({5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2yl}thio)-2H-chromen-2-one; 5-lipoxygenases inhibitor; anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-artherosclerotic agents; angina, cerebral spasm, nephritis, hepatitis |
| 06/01/2006 | US20060116405 Indol derivatives and their use as 5-ht ligands |
| 06/01/2006 | US20060116404 CAI-based systems and methods for the localized treatment of ocular and other diseases |
| 06/01/2006 | US20060116403 Therapeutic target and uses thereof |
| 06/01/2006 | US20060116402 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library |
| 06/01/2006 | US20060116401 Antibacterial compounds |
| 06/01/2006 | US20060116400 Oxazolidinone and/or isoxazoline derivatives as antibacterial agents |
| 06/01/2006 | US20060116399 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 06/01/2006 | US20060116398 E.g., biphenyl-2-ylcarbamic acid 1-{9-[2-(4-hydroxy-2-oxo-2,3-dihydrobenzothiazol-7-yl)ethylamino]nonyl}piperidin-4-yl ester;respiratory system disorders; bronchodilators; chronic obstructive pulmonary disease or asthma; affinity for dopamine D2 receptors; used with phosphodiesterase-4 inhibitor |
| 06/01/2006 | US20060116397 Use of saquinavir as a radiation sensitizer |
| 06/01/2006 | US20060116396 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents |
| 06/01/2006 | US20060116395 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease |
| 06/01/2006 | US20060116394 Fab I inhibitors |
| 06/01/2006 | US20060116393 Substituted pyrido [2,1-a] isoquinoline derivatives |
| 06/01/2006 | US20060116392 Methods for treating anxiety disorders and related article of manufacture |
| 06/01/2006 | US20060116391 adding a solution of calcium chloride with a solution of water soluble an alkali metal or methylamine or ammonium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid; cost efficient; hypercholesterolemia, atherosclerosis |
| 06/01/2006 | US20060116390 Hepatitis c virus inhibitors |
| 06/01/2006 | US20060116389 Antibacterial oxazolidinones |
| 06/01/2006 | US20060116388 CXCR3 antagonists |
| 06/01/2006 | US20060116387 Hydrate of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-a]-pyrimidin-7-yl}phenyl)acetamide and processes and methods related thereto |
| 06/01/2006 | US20060116386 Oxazolidinones as antibacterial agents |
| 06/01/2006 | US20060116385 Novel compounds having selective inhibiting effect at gsk3 |
| 06/01/2006 | US20060116384 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| 06/01/2006 | US20060116383 Integrin antagonists useful as anticancer agents |
| 06/01/2006 | US20060116382 Lactam compounds and their use as pharmaceuticals |
| 06/01/2006 | US20060116381 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases |
| 06/01/2006 | US20060116380 Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| 06/01/2006 | US20060116379 Compounds exhibiting type X sPLA2 inhibiting effect |
| 06/01/2006 | US20060116378 e.g. 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-dicyclopenta[a,g]naphthalene; serotonine (5-HT) reuptake inhibitor, alpha 2-adrenoceptor antagonist; antidepressant, anxiolytic agent; Parkinson's disease, eating disorders, psychosis, obesity |
| 06/01/2006 | US20060116377 Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses |
| 06/01/2006 | US20060116376 Therapy of central nervous disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, anxiety, depression, and schizophrenia and fibromyalgia |
| 06/01/2006 | US20060116375 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury |
| 06/01/2006 | US20060116374 substituted bis/thiohydrazide amide compound; synergistic effect with taxol or taxotere, anticancer agents, side effect reduction |
| 06/01/2006 | US20060116373 Substituted pteridines for the treatment of inflammatory diseases |
| 06/01/2006 | US20060116372 Substituted pteridines for the treatment of inflammatory diseases |
| 06/01/2006 | US20060116371 4-Substituted with a 1-pyrrolyl-, 1-piperidinyl- or 4-piperidinyl ring, e.g., lbenzyl-(6-methoxy-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridin-7-yl)-amine; phosphodiesterase inhibitors with reduced side effects, particularly nausea; respiratory, gastrointestinal, skin, joint, and eye disorders, cancer |
| 06/01/2006 | US20060116370 Substituted pteridines for the treatment of inflammatory diseases |
| 06/01/2006 | US20060116369 Certain compounds, compositions, and methods |
| 06/01/2006 | US20060116368 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor |
| 06/01/2006 | US20060116367 such as Biphenyl-2-carboxylic acid [3-chloro-4-(3-hydroxymethyl-4-methanesulfonyl-2,3,4,5-tetrahydrobenzo[e][1,4]diazepine-1-carbonyl)-phenyl]-amide, used for treating hypertension, congestive heart failure, ischemia, cirrhosis, renal failure, edema, stroke, thrombosis, coronary and renal vasospasm |
| 06/01/2006 | US20060116366 Spirocyclic ureas, compositions containing such compounds and methods of use |
| 06/01/2006 | US20060116365 Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone |
| 06/01/2006 | US20060116364 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer |
| 06/01/2006 | US20060116363 Tricyclic derivatives as ltd4 antagonists |
| 06/01/2006 | US20060116362 Nobel compounds having selective inhibiting effect at gsk3 |
| 06/01/2006 | US20060116361 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation |
| 06/01/2006 | US20060116360 Method of administering anti-angiogenic agents and a method of treating disease using same |
| 06/01/2006 | US20060116359 17.Beta-(alpha-hydroxy)-esters of androstanes as intermediates for the preparation of 17.beta-fluorinated-androstane esters |
| 06/01/2006 | US20060116358 Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders |
| 06/01/2006 | US20060116357 Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate |
| 06/01/2006 | US20060116356 Phosphonate analogs of HIV integrase inhibitor compounds |
| 06/01/2006 | US20060116355 Eye care kit for treating periocular disease |
| 06/01/2006 | US20060116354 Antineoplastic ether lipid compounds with modifications at the sn-3 carbon |
| 06/01/2006 | US20060116352 2alpha-Methyl and 2beta-methyl analogs of 19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and their uses |
| 06/01/2006 | US20060116351 17,20(Z)-dehydro vitamin D analogs and their uses |
| 06/01/2006 | US20060116350 administering a therapeutically effective amount of nafadotride or a pharmaceutically acceptable salt for decreasing gastrointestinal tract motility or gastric emptying in a patient; sustained release agent |
| 06/01/2006 | US20060116349 Methods and compositions for administration of iron for the treatment of restless leg syndrome |
| 06/01/2006 | US20060116348 Using the hyaluronate synthase from Pasteurella multocida; coatings for biomaterials wherein the coatings provide protective properties to the biomaterial and/or act as a bioadhesive; coatings could be applied to electrical devices, sensors, catheters |
| 06/01/2006 | US20060116347 Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| 06/01/2006 | US20060116346 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 06/01/2006 | US20060116345 Antitumor effect potentiator and antitumor agent |
| 06/01/2006 | US20060116344 Remedy and preventive for diseases caused by NF-kB |
| 06/01/2006 | US20060116341 Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity |
| 06/01/2006 | US20060116339 Antisense modulation of purinoreceptor p2x3 |
| 06/01/2006 | US20060116337 Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors |
| 06/01/2006 | US20060116336 Stable, sterile; community-acquired pneumonia or pelvic inflammatory disease |
| 06/01/2006 | US20060116335 Ready-for-complexation composition |
| 06/01/2006 | US20060116334 Folate based composition for treatment of the cardiovascular system |
| 06/01/2006 | US20060116333 Composition for protecting organ, tissue or cell and utilization thereof |
| 06/01/2006 | US20060116332 Methods for inhibition of NKT cells |
| 06/01/2006 | US20060116331 Glycosylceramide analogues |
| 06/01/2006 | US20060116330 Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
| 06/01/2006 | US20060116329 Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
| 06/01/2006 | US20060116328 Combined use of carnosinase inhibitor with l-carnosines and composition |
| 06/01/2006 | US20060116326 Benzothiophene compounds having antiinfective activity |
| 06/01/2006 | US20060116316 Heterocyclic inhibitors of IRES-mediated translation and methods of use thereof |
| 06/01/2006 | US20060115827 Genetic markers for predicting disease and treatment outcome |
| 06/01/2006 | US20060115815 Method and compositions for identifying anti-hiv therapeutic compounds |
| 06/01/2006 | US20060115811 Cytochrome p450ra1-2 and related proteins |
| 06/01/2006 | US20060115571 Functional foods/drinks containing antiallergic component |
| 06/01/2006 | US20060115545 Methods and means for the manufacture of hyaluronan |
| 06/01/2006 | US20060115543 Anti-diabetic extract isolated from Rauvolfia vomitoria and citrus aurantium, and method of using same |
| 06/01/2006 | US20060115542 Therapeutic delivery of carbon monoxide |
| 06/01/2006 | US20060115540 administering (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide; treating urogenital disorders |
| 06/01/2006 | US20060115539 Micropellets method for the production thereof, and use thereof |
| 06/01/2006 | US20060115538 Calcium lactate and whey permeate for lowering the triglyceride level |